GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (NAS:GLYC) » Definitions » Shiller PE Ratio

GlycoMimetics (GlycoMimetics) Shiller PE Ratio : (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GlycoMimetics Shiller PE Ratio Historical Data

The historical data trend for GlycoMimetics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics Shiller PE Ratio Chart

GlycoMimetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlycoMimetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlycoMimetics's Shiller PE Ratio

For the Biotechnology subindustry, GlycoMimetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoMimetics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's Shiller PE Ratio falls into.



GlycoMimetics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

GlycoMimetics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, GlycoMimetics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.14/129.4194*129.4194
=-0.140

Current CPI (Dec. 2023) = 129.4194.

GlycoMimetics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.300 99.695 -0.389
201406 0.390 100.560 0.502
201409 -0.350 100.428 -0.451
201412 -0.390 99.070 -0.509
201503 -0.370 99.621 -0.481
201506 0.510 100.684 0.656
201509 -0.380 100.392 -0.490
201512 -0.470 99.792 -0.610
201603 -0.400 100.470 -0.515
201606 -0.410 101.688 -0.522
201609 -0.340 101.861 -0.432
201612 -0.360 101.863 -0.457
201703 -0.340 102.862 -0.428
201706 -0.300 103.349 -0.376
201709 -0.240 104.136 -0.298
201712 -0.270 104.011 -0.336
201803 -0.330 105.290 -0.406
201806 -0.260 106.317 -0.316
201809 -0.270 106.507 -0.328
201812 -0.320 105.998 -0.391
201903 -0.330 107.251 -0.398
201906 -0.370 108.070 -0.443
201909 -0.310 108.329 -0.370
201912 -0.340 108.420 -0.406
202003 -0.180 108.902 -0.214
202006 -0.320 108.767 -0.381
202009 -0.290 109.815 -0.342
202012 -0.320 109.897 -0.377
202103 -0.280 111.754 -0.324
202106 -0.280 114.631 -0.316
202109 -0.340 115.734 -0.380
202112 -0.330 117.630 -0.363
202203 -0.280 121.301 -0.299
202206 -0.250 125.017 -0.259
202209 -0.160 125.227 -0.165
202212 -0.190 125.222 -0.196
202303 -0.170 127.348 -0.173
202306 -0.130 128.729 -0.131
202309 -0.140 129.860 -0.140
202312 -0.140 129.419 -0.140

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlycoMimetics  (NAS:GLYC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


GlycoMimetics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoMimetics (GlycoMimetics) Business Description

Traded in Other Exchanges
Address
9708 Medical Center Drive, Rockville, MD, USA, 20850
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
Executives
Edwin Rock officer: Chief Medical Officer 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Brian M. Hahn officer: CFO C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Daniel M Junius director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Bruce S Johnson officer: SVP & Chief Commercial Officer 9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850
Chinmaya Rath officer: SVP and Chief Business Officer 9708 MEDICAL CENTER DR., ROCKVILLE MD 20850
Invus Public Equities, L.p. 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Invus Public Equities Advisors, Llc 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Artal Group S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
S.a. Westend 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Administratiekantoor Westend Stichting 10 percent owner CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD
Artal International Management S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Amaury Wittouck 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661
Scott D Sandell 10 percent owner
Harout Semerjian director, officer: Chief Executive Officer 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950

GlycoMimetics (GlycoMimetics) Headlines

From GuruFocus